BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alzamend Neuro readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Alzamend Neuro's drugs run\, from
  ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07540338-10983@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Lithium salicylate/L-proline (AL001): Phase 1/2 readout est. (NCT07
 540338)
DESCRIPTION:Lithium salicylate/L-proline (AL001)\, phase 1/2\, Bipolar Diso
 rder.\nStudy: A Study to Investigate Lithium Brain/Plasma Pharmacokinetics
  and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-rele
 ase Lithium Carbonate Capsule in Subjects With Bipolar I Disorder\nEstimat
 ed primary completion: July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lithium-salicylate-l-proline-al001#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07540338
URL:https://assetmemo.bio/drug/lithium-salicylate-l-proline-al001#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
